
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...

How microplastic particles get into the body
Microplastic particles exposed to freshwater or saltwater environments for several weeks are about ten times more likely than pristine particles to...

Galecto raise US$85m in Nasdaq IPO
The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

Global bioeconomy in the spotlight
Whereas first editions of the summit took place in Berlin in 2015 and 2018, the third edition was organized as a digital conference week from 16th to...

Evotec expanding at Milton Park campus
According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

Transgene reports clinical results of TG4001 plus avelumab
Combination of TG4001 and Merck KGaA’s checkpoint inhibitor avelumab demonstrated anti-tumour activity in patients with previously treated recurrent...